Therapeutic Resistance in Melanoma: Molecular Mechanisms and Emerging Pharmaceutical Strategies
Cutaneous melanoma remains a global health challenge. Although BRAF/MEK-targeted therapies and immune checkpoint inhibitors (ICIs) have improved outcomes in advanced disease, durable responses remain difficult to achieve for most patients. Therapeutic resistance represents the central barrier to long-term disease contr...